FDA approves first plasmid DNA therapy after 7 of 26 patients avoided surgery

The Food and Drug Administration granted accelerated approval Friday to Voceryq, the first plasmid DNA-based immunotherapy approved in the United States. The medicine is authorized to reduce the frequency of surgical papilloma removal in adults with recurrent respiratory papillomatosis, a rare disease in which human papillomavirus causes growths in the airway.

The result behind the decision is promising but narrow. In an open-label, single-arm study of 32 adults, 26 patients had needed at least three surgeries in the year before treatment. Seven of those 26, or 27%, required no surgery during the first year after treatment, according to the FDA's approval announcement. There was no randomized control group, and continued approval depends on further evidence.

What the therapy does

Voceryq contains two DNA plasmids designed to express antigens from HPV types 6 and 11, along with a protein intended to enhance the immune response. The prescribing information says the medicine is injected into muscle on Day 0 and at Weeks 3, 6 and 9. A delivery device then uses brief electrical pulses, a technique called electroporation, to help the plasmids enter cells.

The product does not carry an approval to eliminate HPV or to guarantee that surgery will stop. Its labeled indication is more specific: reduce the frequency of surgical papilloma excisions in adults. That distinction matters because the approval rests on whether patients needed further operations, not on a completed comparison showing that the treatment cures the disease or improves every symptom.

The number behind the approval

All 32 participants had undergone at least two surgeries in the prior 12 months, including a surgery at trial entry. The efficacy group was the 26 who had undergone at least three. Inovio said the median before treatment was 4.5 excisions, with a range of three to eight. Seven had no excision during the following 12 months, producing the 27% complete-response result cited by FDA.

The small denominator is the strongest limitation. Seven patients can establish a regulatory signal in a rare disease, but a 26-person efficacy group cannot answer every question about how reliably the benefit will repeat across ages, disease severity and clinical settings. The study was open-label and single-arm, so every participant and investigator knew treatment was given, and the comparison was with patients' prior surgical history rather than a concurrently randomized group.

Safety and the practical burden

The most common adverse reaction was an injection-site reaction, reported in 11 of 32 patients, or 34%. Headache occurred in six patients, fatigue in five, hypertension in four, and nausea and dizziness in two each. The label also warns that electroporation can cause muscle contractions, temporary bleeding, anxiety, lightheadedness and pain at the treatment site. Safety and effectiveness have not been established in pediatric patients.

For adults cycling through repeated airway procedures, the meaningful benefit is fewer operations, not simply a laboratory marker. The therapy still requires an initial standard-of-care removal of visible papillomas and four treatment visits over nine weeks. Inovio said it expects the medicine to be available to order and ship in about 60 days, with a full commercial launch in the first quarter of 2027. That is a company timetable, not an FDA guarantee, and the release did not provide a price.

The trial that will decide whether the benefit holds

The approval letter requires an adequate, controlled study with at least 50 adult and pediatric patients who needed three or more interventions in the prior year. It must track surgeries for at least three years after treatment and compare the result with an external control group or a scientifically justified threshold. FDA says it may withdraw approval if the study fails to verify clinical benefit or is not conducted diligently.

The first checkpoint comes quickly: a draft protocol is due December 30, 2026, and a final protocol is due June 30, 2027. Study completion is scheduled for December 30, 2031, with the final report due August 30, 2032. Those dates define the real evidence test. The approval gives eligible adults a new option now, while leaving the durability and broader applicability of the benefit to a larger, longer study.

Sources: the FDA's approval announcement, approval letter and prescribing information, plus Inovio's commercial and study disclosure. This report is general information, not medical advice.